We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current CHGCY market cap is 51.27B. The company's latest EPS is JPY 98.9687 and P/E is 0.33.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 686.18B | 787.01B | 999.76B | 1.26T | 1.14T |
| Operating Income | 210.6B | 301.23B | 419.36B | 531.18B | 439.17B |
| Net Income | 157.56B | 214.73B | 303B | 374.43B | 325.47B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.06T | 1.24T | 1.54T | 1.87T | 1.93T |
| Total Liabilities | 204.93B | 255.5B | 350.68B | 445.37B | 306.97B |
| Total Equity | 853.99B | 980B | 1.19T | 1.42T | 1.63T |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 206.64B | 205.04B | 279.63B | 244.11B | 409.93B |
| Investing | -81.74B | -98.31B | -118.93B | -145.99B | -37.29B |
| Financing | -66.87B | -99.5B | -107.41B | -145.64B | -139.33B |
| Market Cap | 51.27B |
| Price to Earnings Ratio | 0.33 |
| Price to Sales Ratio | 0.09 |
| Price to Cash Ratio | 0.23 |
| Price to Book Ratio | 0.07 |
| Dividend Yield | - |
| Shares Outstanding | 3.29B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.08 (0.51%) |
| Company Name | Chugai Pharmaceutical Ltd (PK) |
| Address |
2-1-1 muromachi-nihonbashi chuo, tokyo 103-8324 |
| Website | https://www.chugai-pharm.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
